All In Biotech

NDA 203567 · Bausch

Jublia

Efinaconazole · Topical · Azole Antifungal

Novel

Last checked: Nov 20, 2026Latest source record: Mar 31, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Jun 6, 2014

Approved uses

2

Original approval plus efficacy supplements

Registered trials

7

1 Phase 3, 0 recruiting

FAERS reports

1,962

727 serious, 108 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 1, 2025.

JUBLIA (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes . JUBLIA is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes . (1)

Mechanism: JUBLIA topical solution is an azole antifungal [ see Clinical Pharmacology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • JUBLIA · EFINACONAZOLE 10% · SOLUTION, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Efinaconazole" as an intervention, any sponsor and status, largest first.

All 7 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective423
  • fatigue244
  • pain234
  • headache214
  • asthenia209
  • drug hypersensitivity183
  • oedema peripheral180
  • anaemia172
  • pyrexia170
  • product dose omission issue166
  • asthma163
  • tremor163

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201427
2015314
2016329
2017163
2018133
201999
2020105
2021131
2022119
2023163
2024154
2025133
202692

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Jublia (Efinaconazole)

2024 spending

$119M

Beneficiaries

35,400

101,398 claims

Per beneficiary

$3,350

$185.16 per unit

View as table
YearSpending
2020$41,729,297
2021$50,336,999
2022$69,225,105
2023$93,684,777
2024$118,601,786

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 33 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.